🇺🇸 glucocerebrosidase in United States
3 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 20 April 2025 – 20 April 2026
- Total reports: 3
Most-reported reactions
- Condition Aggravated — 1 report (33.33%)
- Cytokine Release Syndrome — 1 report (33.33%)
- Parainfluenzae Virus Infection — 1 report (33.33%)
Other Neuroscience approved in United States
Frequently asked questions
Is glucocerebrosidase approved in United States?
glucocerebrosidase does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for glucocerebrosidase in United States?
National Center for Research Resources (NCRR) is the originator. The local marketing authorisation holder may differ — check the official source linked above.